Shikari® Avelumab ELISA Kit

$1,315.00

The Shikari® Avelumab ELISA Kit is intended for the quantitative determination of Avelumab in serum and plasma samples between the Cmin and Cmax range of concentrations. The Shikari® Avelumab ELISA Kit is for research use only and not to be used for diagnostic procedures.

SKU: AVE-FD-BAV Category: Tags: , , ,

Avelumab is a fully human monoclonal IgG1 lambda antibody that targets programmed death-ligand 1 (PD-L1), a key immune checkpoint protein expressed on tumor cells and immune cells within the tumor microenvironment. By binding to PD-L1 through its FG loops, avelumab blocks the interaction between PD-L1 and its receptors PD-1 and B7.1. This blockade removes the inhibitory signals on T cells, thereby restoring anti-tumor immune responses, including T-cell proliferation, cytokine release, and cytotoxic activity.

Unlike some other immune checkpoint inhibitors, avelumab also induces antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro, adding a direct tumor-killing mechanism in addition to immune modulation. Preclinical studies in syngeneic mouse tumor models have shown that blocking PD-L1 with avelumab results in decreased tumor growth, supporting its role in cancer immunotherapy.

In research and clinical practice, therapeutic drug monitoring (TDM) of avelumab is useful for maintaining optimal drug levels in patients, especially in long-term or combination therapy settings. Monitoring helps optimize efficacy, manage adverse effects, and detect anti-drug antibodies (ADAs) that may reduce drug effectiveness or alter pharmacokinetics. As a biologic product, avelumab’s production involves complex, cell-based systems, and its immunogenicity profile may vary with even minor manufacturing differences—highlighting the importance of consistency in formulation and the challenges in biosimilar development.

This product is manufactured in Turkey by Matriks Biotek.

Size 1 x 96 Well
Sensitivity 0.03µg/mL
Dynamic Range 10-300 µg/mL
Incubation Time 1 hour 10 minutes
Sample Type Serum, Plasma
Immunogen
Source Species
Specificity
Expression System
Clone
Group
Alpha Chain
Beta Chain
Peptide
Peptide Source
Format
Buffer
Concentration
Storage 2-8°C
Alternative Names Avelumab, Bavencio, anti-PD-L1 antibody, fully human IgG1 lambda monoclonal antibody, PD-L1 immune checkpoint inhibitor, programmed death-ligand 1 blocker, MSB0010718C.
Instructions For Use https://eaglebio.com/wp-content/uploads/2025/06/AVE-FD-BAV-shikari-avelumab-elisa-instructions-for-use-1.pdf
MSDS https://eaglebio.com/wp-content/uploads/2025/06/AVE-FD-BAV-shikari-avelumab-elisa-safety-data-sheet.pdf

Product Citations